Table 1.
Demographic and clinical information for all study participants
| CON (n=12) | psALS (n=12) | ALS (n=12) | |
|---|---|---|---|
| Age (years) | 47.8±12.6 (20–65) | 47.8±12.4 (20–65) | 47.8±8.5 (31–64) |
| Gender | 10 F: 2 M | 10 F: 2 M | 6 F: 6 M |
| Gene mutation | NA | 10 SOD1 2 C9ORF72 |
NA |
| Site of symptom onset | NA | NA | 2 Bulbar 2 RUL, 1 LUL, 5 RLL, 2 LLL |
| ALSFRS-R | NA | NA | 33.8±4.5 (21–38) |
| Disease duration from symptom onset (months) | NA | NA | 47.0±35.1 (13–123) |
| Progression rate (48—ALSFRS-R / duration in months) | NA | NA | 0.47±0.29 (0.11–0.94) |
Values are given as mean±SD (range).
ALSFRS-R, revised Amyotrophic Lateral Sclerosis Functional Rating Scale; CON, control; LLL, left lower limb; LUL, left lower limb; NA, not applicable; RLL, right lower limb; RUL, right upper limb.